| Gene name: | TOP2A |
| Aging type: | Prevent |
| Aging characteristic: |
| Tissue type: | -- |
| Cell name: | U2OS,HeLa |
| Experiment: | TRF assay |
| Description: | TOP2a or TOP2b downregulated U2OS cells displayed telomere shortening phenotypes compared to control cells. |
| Target gene: | TIFS |
| Official symbol(s): | TIFS |
| R-AG-Target gene: | Downregulation |
| Subcategory: | Unclear |
| Target gene experiment: | FISH//Immunostaining |
| Target gene description: | Increases in TIFs were observed in shTOP2a and shTOP2b ALT cancer cells but not in telomerase-positive cells. |
| Regulatory pathway: | ALT |
| R-AG-Pathway: | -- |
| Official symbol(s): | ALT |
| Pathway experiment: | Survival curve//Southern blot//FISH//Immunostaining |
| Pathway description: | ICRF-193-treated ALT cells displayed an inhibition of proliferation in a dose-dependent manner. Telomere shortening was also observed in ICRF-193-treated ALT cells, but not in telomerase-positive cells. We next measured the numbers of APBs and TIFs to determine whether the ALT pathway is affected in drug-treated ALT cells. ICRF-193 treatment decreased APBs and increased TIFs in ALT cells. These findings suggest that TOP2s participate in telomere–telomere recombination and that ALT cells are more sensitive to the TOP2 inhibitor than telomerase-positive cancer cells. |
Annotation:
Loading,please wait...